Processing...
All Trials
Search
Search
There are 1731 active trials in our database.
Click on a trial to see more information.
1731 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with ECOG 0–1 and refractory/relapsed locally advanced unresectable or metastatic solid tumors, including post–PD-1/PD-L1 treated RCC, HCC, gastroesophageal cancer, and endometrial cancer, receive CTX-10726 monotherapy IV every 2 weeks. CTX-10726 is an investigational tetravalent bispecific antibody targeting PD-1 and VEGF-A to combine checkpoint blockade with anti-angiogenic activity.
ClinicalTrials.gov ID: NCT07419841
TrialFetch AI summary: Adults with previously treated unresectable HCC (BCLC C or B not suitable for locoregional therapy), Child-Pugh A, ECOG 0-1, and measurable disease undergo RYZ811 gallium-68 PET to identify GPC3-positive tumors. Eligible patients receive RYZ801, an actinium-225 GPC3-targeted alpha-emitting radiopharmaceutical, with dose escalation/expansion and randomized comparison against standard-of-care systemic therapy.
ClinicalTrials.gov ID: NCT06726161
TrialFetch AI summary: Adults with advanced measurable solid tumors who have exhausted or are ineligible for standard therapies, with a melanoma-focused expansion requiring known BRAF status and generally ≤3 prior systemic lines. All patients receive BI 3810944 monotherapy, an investigational small-molecule anticancer agent with undisclosed target/mechanism, given initially weekly then typically every 3 weeks.
ClinicalTrials.gov ID: NCT07224425
TrialFetch AI summary: Adults with stage III/IV NSCLC and ECOG 0–1 after prior advanced-setting therapy including anti–PD-1/PD-L1, with secondary/acquired ICI resistance; later cohorts require prior platinum chemotherapy and docetaxel as third-line population. Treatment is IV THIO, an investigational telomere-targeting 6-thio-dG that induces telomere dysfunction/DNA damage in telomerase-positive tumor cells, given alone or sequenced before cemiplimab anti–PD-1.
ClinicalTrials.gov ID: NCT05208944
TrialFetch AI summary: Open-label dose-escalation/expansion study of oral TRI-611, a brain-penetrant ALK molecular glue degrader that promotes cereblon-mediated degradation of ALK fusion proteins, in adults with advanced measurable ALK-positive NSCLC. Cohorts include heavily ALK TKI–pretreated patients, including post-lorlatinib and post-neladalkib settings, as well as an ALK TKI–naïve cohort; stable CNS metastases are allowed.
ClinicalTrials.gov ID: NCT07491497
TrialFetch AI summary: Adults with advanced/metastatic PTK7-expressing solid tumors, including non-squamous EGFR-wild-type NSCLC, platinum-resistant ovarian cancer, and endometrial carcinoma, receive HWK-007 IV every 3 weeks. HWK-007 is an investigational PTK7-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload, with dose escalation/expansion focused on safety, dose selection, pharmacokinetics, immunogenicity, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07444814
TrialFetch AI summary: Enrolls adults with ECOG 0–1 and advanced c-Met–expressing solid tumors after standard therapy, with expansion cohorts emphasizing MET-amplified and/or c-Met–overexpressing nonsquamous NSCLC after prior platinum, immunotherapy, and targeted therapy when applicable. All patients receive CKD-703, a c-Met–targeted antibody–drug conjugate delivering the microtubule toxin MMAE.
ClinicalTrials.gov ID: NCT07439094
TrialFetch AI summary: First-in-human dose-escalation trial of injectable BI 3820768, an investigational immune-directed anticancer biologic with limited public target/mechanism details, given weekly for two 3-week cycles then every 3 weeks. Enrolls ECOG 0–1 adults with advanced relapsed/refractory germ cell tumors, endometrial cancer, or ovarian cancer after standard options; endometrial and ovarian cohorts require centrally confirmed target-positive tumors.
ClinicalTrials.gov ID: NCT07306559
TrialFetch AI summary: Adults with advanced/metastatic solid tumors, initially ovarian cancer and endometrial carcinoma, receive IV HWK-016, a first-in-human MUC16-directed antibody–drug conjugate carrying a topoisomerase I inhibitor payload. Ovarian cancer cohorts may also receive HWK-016 combined with bevacizumab, with dose escalation/expansion focused on safety, recommended dose, pharmacokinetics, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07470853
TrialFetch AI summary: Enrolls adults with SSTR-PET–positive, well-differentiated grade 1–3 metastatic or unresectable neuroendocrine tumors, with expansion cohorts including GEP-NETs, other SSTR-expressing NETs, and grade 1–3 meningiomas; prior radiopharmaceutical therapy such as lutetium-177 is excluded. Treatment is IV RYZ401, an investigational actinium-225–labeled somatostatin receptor–targeted alpha radiopharmaceutical designed to deliver radiation to SSTR/SSTR2-expressing tumor cells, given approximately every 6 weeks for 2–4 cycles.
ClinicalTrials.gov ID: NCT07165132